Cellipont Bioservices
Deborah Wild has a strong background in the biopharmaceutical industry with over 30 years of experience. Currently, they serve as the President and Chief Executive Officer at Cellipont Bioservices. Previously, in 2021, they founded their own company, DW BioPharma, LLC., where they were the Business Owner. Deborah also held the position of President and CEO at Performance Cell Manufacturing for a brief period in 2021.
In 2021, Deborah served as the Executive Chair of the Board at CoreRx, Inc. Before that, they worked at Catalent Pharma Solutions from 2019 to 2020, first as the Global Head of Client and Business Management for Catalent Cell and Gene Therapy, and later as the Chief of Staff for Paragon Gene Therapy - Corporate Development.
Prior to their role at Catalent, Deborah worked at Paragon Bioservices, Inc. as the Chief Quality and Regulatory Affairs Officer from 2019 to 2019 and the Sr. Vice President of Quality and Regulatory Affairs from 2017 to 2018.
From 2009 to 2015, they held the role of Vice President of Quality at Polynoma LLC, where they developed and managed the company's Quality Control and Assurance System and ensured regulatory compliance with contract manufacturing organizations and contract research organizations.
Deborah also has experience at Victory Pharma, Inc., where they were the VP of Manufacturing and Supply Chain from 2006 to 2009.
Their early career includes a long tenure at Genentech, where they held various positions, including Director of Contract Manufacturing and Manager of Sterile Filling. During their time at Genentech, they managed multiple contract manufacturing sites and was responsible for the bulk and final biological drug processing.
Before their career in the biopharmaceutical industry, Deborah served in the US Army as a Staff Sergeant from 1984 to 1992.
Deborah Wild has pursued their education in the field of Sociology at Austin Peay State University. However, no specific start or end year for their education at this institution is mentioned.
This person is not in any teams
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with more than 15 years’ experience in the development and small-to-large batch manufacturing of cell therapies. Our leaders have played an instrumental role in shaping cell therapy development and manufacturing methods and technologies, and our technically-strong team has been recognized by customers and technology partners for its ability to productively grow challenging cells. Cellipont is driven to help our clients to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. We are a small company with a culture that is extremely responsive and customer-centric. Despite our size, Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 900 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont’s growth with deep knowledge of what it takes succeed in this space. Cellipont Bioservices facilities and quality systems are GMP-compliant and we hold a California Food & Drug Branch manufacturing license. We have extensive experience in multiple product areas, including CAR-T, iNK, dendritic cell, & other novel cell therapy approaches. OUR NAME: By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of what we are all about: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. As we finalize our corporate rebranding, we look forward to launching a new website in the coming weeks to better share our vision with you.